iFabric Corp. provided an update on the outcome of the clinical trial conducted by its wholly-owned subsidiary, Intelligent Fabric Technologies (North America) Inc. ("IFTNA"). The objective of the trial was to empirically demonstrate the reduction in bacterial loads on PROTX2 treated scrubs vs standard off the shelf untreated scrubs, when used in a healthcare environment.

Three sets of scrubs were produced for the trial; one set treated with ProTX2 only, a second set with Protx2 and proprietary DWR (durable water repellant) technology and, a third set with no technologies applied (the control). The summary of the trial findings is that both the PROTX2 and the PROTX2 with DWR treated scrubs demonstrated statistically significant reductions in bacterial loads on the surfaces of scrubs, as compared to untreated scrubs. The term statistically significant is used to describe a result that is highly unlikely to occur by chance alone in a natural environment.

The results achieved in the study demonstrate that proprietary technologies were uniquely responsible for the reduction in bacterial loads witnessed throughout the trial. The next and final phase of this trial is to submit the study to a recognized medical journal for peer review.